Tag Archives: BIO CEO & Investor Conference

BIO CEO Company Snapshot: Tetraphase Pharmaceuticals

tetraphase

The BIO CEO & Investor Conference is now just a week away, and buzz for the event has never been greater. Tomorrow, Inside BIO is hosting its first ever twitter chat to discuss the annual buyside survey, which has been getting great responses from the investor community. Presentation spots are still sold out as well, and we’re continuing to highlight those companies slated to present. One such company is Tetraphase Pharmaceuticals, who went public this Read More >

The One-on-One Compass  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

2013 Novel Drug Approvals

Therapeutic-Indications-with-Novel-Drug-Approvals-in-2013-115x76

The FDA approved 24 novel drugs last year by our count, in line with average approvals for the last ten years but down from the decade-high approvals seen in 2012. Our count is a bit lower than the FDA’s count of 27 new approvals, because we did not include imaging agents like Navidea’s Lymphoseek, or reformulations like J&J’s Simponi Aria. 2013 was the first year the breakthrough-designated therapies were approved, with three breakthrough therapies approved: Gilead’s Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,

#BIOBuyside Twitter Chat: What Do Biotech Investors Expect in 2014?

Dave Thomas

Is 2014 a good time to invest in biotech? How many biotech IPOs will there be? Which sectors will perform the best? To find out what investors think about these questions and more, BIO is conducting its annual Buy-side Investor Perception Survey and releasing the results at the 16th Annual BIO CEO & Investor Conference in New York, Monday Feb. 10. But as the results are coming in, BIO is hosting the #BIOBuyside Twitter chat Read More >

Inside BIO Industry Analysis  |  2 Comments  |  Email This Post
Tags: , , , , , , , , , ,

What’s In Store for Biotechs at this Year’s CEO & Investor Conference

CEO2014_blog copy

In just a few weeks, industry leaders will gather in New York for one of BIO’s largest and most successful events, the 16th Annual BIO CEO & Investor Conference. As we’ve seen at JPMorgan, the extraordinary performance of biotech equities for the past several years has generated a great deal of interest among investors to work with biotech companies to foster innovation in the coming year. This year’s event is shaping up to be even Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , ,

Couldn’t Make it to San Francisco This Week?

20070112

Me neither, so here is what I am reading for updates about the 32nd Annual JPMorgan Healthcare Conference. Before arriving, hopefully you read the survival guide put forth by the InVivo blog team. In it, Chris Morrison and team outlined a few helpful talking points to help you when running in to industry colleagues. Likewise, Luke Timmerman, from Xconomy, has all the industry news you need to know heading in to the event, perhaps most importantly; who he thinks should Read More >

Business and Investments, Events  |  1 Comment  |  Email This Post
Tags: , , , , ,